The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Adage Capital Management, L.P. and affiliates reported their ownership in Traws Pharma, Inc. common stock. The group, consisting of Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross, collectively reported beneficial ownership of 730,000 shares of Traws Pharma common stock.
This position represents 4.79% of the outstanding common stock, based on 15,228,328 shares outstanding as of June 30, 2026, as referenced from a company prospectus. The shares are held through Adage Capital Partners, L.P., with the reporting persons having shared voting and dispositive power over 730,000 shares and no sole voting or dispositive power. The reporting group states that they now hold 5 percent or less of the class, and they include customary language that the filing should not itself be construed as an admission of beneficial ownership beyond what is reported.
Traws Pharma, Inc. reported that on July 29, 2026 it received a notification letter from the Nasdaq Listing Qualifications Department stating that its common stock is not in compliance with the Nasdaq Capital Market minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price has been below $1.00 per share for at least 30 consecutive business days. The notice does not immediately affect the company’s Nasdaq listing.
Traws Pharma has 180 calendar days, until January 25, 2027, to regain compliance, which requires a closing bid price at or above $1.00 per share for at least 10 consecutive business days, a period Nasdaq may extend to up to 20 days. If compliance is not regained, Nasdaq may grant a second 180‑day grace period if other listing standards are met and the company plans to cure the deficiency. Otherwise, the stock may be subject to delisting, which the company could appeal. Traws Pharma states it will monitor its bid price and consider options, but there is no assurance of regaining compliance.
Traws Pharma, Inc. reported a compensation-related insider transaction for Chief Science Officer Virology Charles David Pauza. He received a grant of 97,000 stock options on July 9, 2026, with an exercise price of $0.68 per share, vesting 100% on July 9, 2027 and expiring July 9, 2036. Following the award, he directly holds options for 97,000 underlying shares of common stock.
Traws Pharma, Inc. director Werner Cautreels received a grant of stock options to acquire 14,150 shares of common stock at an exercise price of $0.68 per share. The options, granted on July 9, 2026 under the 2021 Incentive Compensation Plan, vest 100% after one year and expire on July 9, 2036, leaving him holding options for 14,150 shares directly.
Traws Pharma, Inc. reported that Chief Operating Officer Nikolay Savchuk received a grant of stock options covering 93,000 shares of common stock on July 9, 2026. The options have an exercise price of $0.68 per share, expire on July 9, 2036, and vest 100% on the first anniversary of the grant date.
Traws Pharma, Inc. director Jack E. Stover received a grant of stock options for 14,150 shares of common stock on July 9, 2026. The options have a $0.68 exercise price, were awarded under the 2021 Incentive Compensation Plan, and were granted at $0.00 per option as compensation. They vest 100% on the first anniversary of the grant date and expire on July 9, 2036. Following this award, Stover directly holds options covering 14,150 shares.
Traws Pharma, Inc. granted its Chief Executive Officer and director, Iain D. Dukes, stock options covering 274,000 shares of common stock with an exercise price of $0.68 per share under its 2021 Incentive Compensation Plan.
The options vest 100% on the first anniversary of the July 9, 2026 grant date and expire on July 9, 2036, leaving Dukes holding 274,000 options following this award.
Traws Pharma, Inc. granted Chief Medical Officer Robert Redfield a stock option award covering 84,000 shares of common stock. The options have an exercise price of $0.68 per share and expire on 2036-07-09. The award was granted at a transaction price of $0.00 per option under the company’s 2021 Incentive Compensation Plan, as amended. According to the award terms, the options will vest 100% on the first anniversary of the 2026-07-09 grant date. Following this grant, Redfield directly holds options for 84,000 underlying shares.
Traws Pharma, Inc. reported that Chief Financial Officer Parker Charles Nolan received a grant of 90,000 stock options to purchase common stock. The options have an exercise price of $0.68 per share, vest 100% on the first anniversary of the July 9, 2026 grant date, and expire on July 9, 2036. The award was approved by the compensation committee of independent directors under the company’s 2021 Incentive Compensation Plan. Following this grant, Nolan holds 90,000 stock options directly.
Traws Pharma director Mary Teresa Shoemaker received a grant of stock options for 14,150 shares of common stock on July 9, 2026 at an exercise price of $0.68 per share. Granted under the 2021 Incentive Compensation Plan, the options vest 100% on the first anniversary of the grant date and expire on July 9, 2036, and are held directly.